Remarkable Intracranial Response to Sotorasib in a Patient With KRAS(G12C)-Mutated Lung Adenocarcinoma and Untreated Brain Metastases: A Case Report

Sotorasib is a KRAS(G12C) inhibitor that recently received approval for use in locally advanced or metastatic KRAS(G12C)-mutated NSCLC. CodeBreaK100, the phase 2 clinical trial leading to the approval of sotorasib, excluded patients with untreated brain metastases; there have been no reports describ...

Descripción completa

Detalles Bibliográficos
Autores principales: Yeh, Justin, Marks, Jennifer A., Alzeer, Ali H., Sloan, Emily A., Varghese, Reshma, Paudel, Nitika, Reuss, Joshua E., Bergquist, Peter J., Liu, Stephen V., Kim, Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719091/
https://www.ncbi.nlm.nih.gov/pubmed/36471683
http://dx.doi.org/10.1016/j.jtocrr.2022.100428

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719091/
https://www.ncbi.nlm.nih.gov/pubmed/36471683
http://dx.doi.org/10.1016/j.jtocrr.2022.100428

Ejemplares similares